EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader

Yuehui Li, Yu Du, Ping Deng, Yi Yang, Yue Wu, Xiaomeng Sun, Qiuzhu Chen, Juntong Yang, Qihua Zhu, Zongjie Gan, Rui Long

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.110495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Yuehui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 4, Drug Design, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activation of the FGFR4 signaling pathway, often driven by FGFR4 genetic alterations, has been implicated in the progression of hepatocellular carcinoma (HCC), highlighting FGFR4 as a promising therapeutic target for FGFR4-driven HCC. Although numerous selective covalent FGFR4 inhibitors have been discovered, developing FGFR4 PROTACs could offer great advantages as an alternative and complementary strategy for HCC therapy. In this study, we have designed a series of covalent degraders by conjugating the FGFR4-selective inhibitor H3B-6527 to E3 ubiquitin ligase-recruiting ligands via diverse linkers. Among them, we identified compound V1 as the first PROTAC capable of degrading FGFR4, with a DC₅₀ value of 0.84 μM and Dmax rate of 80%. Further evaluation demonstrated that V1 promotes efficient and sustained FGFR4 degradation through a ubiquitin-proteasome system (UPS)-dependent pathway and exhibited moderate inhibitory effects on cell proliferation in JHH-7 cells. Moreover, the covalent binding model of compound V1 with FGFR4 was also characterized by LC-MS/MS. These findings suggest that V1 is a promising lead compound for the development of FGFR4-targeted PROTACs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 4Drug DesignAntineoplastic AgentsProtein Kinase InhibitorsHumansProteolysis Targeting ChimeraCell ProliferationStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugDrug Screening Assays, AntitumorCell Line, TumorProteolysis

Stichwörter der Autor:innen

Covalent degraderFGFR4HCCPROTAC

Substanzen

Receptor, Fibroblast Growth Factor, Type 4Proteolysis Targeting ChimeraFGFR4 protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
  • State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, PR China.
  • Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China.
  • Chongqing Key Laboratory of Quality Control and Safety Evaluation of APIs, Chongqing Medical University, Chongqing 400016, PR China.
  • State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, PR China. Electronic address: zhuqihua@cpu.edu.cn.
  • Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; Chongqing Key Laboratory of Quality Control and Safety Evaluation of APIs, Chongqing Medical University,…

Förderung

  • Natural Science Foundation of Chongqing Municipality

Zitieren

APA

Li, Y., Du, Y., Deng, P., Yang, Y., Wu, Y., Sun, X., Chen, Q., Yang, J., Zhu, Q., Gan, Z., & Long, R. (2026). Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110495

Vancouver

Li Y, Du Y, Deng P, Yang Y, Wu Y, Sun X, et al. Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110495

BibTeX
@article{Li2026,
  author = {Li, Yuehui and Du, Yu and Deng, Ping and Yang, Yi and Wu, Yue and Sun, Xiaomeng and Chen, Qiuzhu and Yang, Juntong and Zhu, Qihua and Gan, Zongjie and Long, Rui},
  title = {Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.110495}
}
Kostenlos starten →